Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

NCT05888103 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hypercholesterolemia or Mixed Dyslipidemia

Interventions

DRUG: Inclisiran
DRUG: Matching Placebo for Inclisiran

Sponsor

Novartis Pharmaceuticals